By: Daniel Trecroci
For type 2s who suffer from kidney disease, treatment with ruboxistaurin was shown to reduce albuminuria and maintain estimated glomerular filtration rate (eGFR) for more than one year. Ruboxistaurin—a PKC inhibitor manufactured by Eli Lilly and Company—may have added benefit in established therapies for diabetic kidney disease.
Researchers at the Heart Institute and Sacred Heart Medical Center in Spokane, Washington, conducted a randomized double-blind placebo-controlled multicenter study to evaluate the effects of 32 mg per day of ruboxistaurin for one year in 123 people with type 2 diabetes and persistent albuminuria despite therapy with renin-angiotensin system inhibitors.
After one year, urinary albumin-to-creatinine ratio (ACR) decreased 24 percent in participants treated with ruboxistaurin compared to 9 percent in the placebo group. Participants’ eGFR did not decline significantly in the ruboxistaurin group, whereas the placebo group lost significant eGFR over one year.
—Diabetes Care, November 2005